{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '15. Pregnant or breastfeeding women.', '16. Women of childbearing potential* who are unwilling to practice highly effective', 'contraception prior to the initial study drug treatment, during the study, and for at least', '6 months after the last dose. Highly effective contraceptive measures include stable use of', 'combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal,', 'transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable)', 'associated with inhibition of ovulation initiated 2 or more menstrual cycles prior to', 'screening; intrauterine device; intrauterine hormone-releasing system; bilateral tubal', 'ligation; vasectomized partner; and or sexual abstinencet, $', '* Postmenopausal women must be amenorrheic for at least 12 months in order not to be', 'considered of childbearing potential. Pregnancy testing and contraception are not required', 'for women with documented hysterectomy or tubal ligation.', '+', 'Sexual abstinence is considered a highly effective method only if defined as refraining', 'from heterosexual intercourse during the entire period of risk associated with the study', 'treatments. The reliability of sexual abstinence needs to be evaluated in relation to the', 'duration of the clinical trial and the preferred and usual lifestyle of the patient.', 'I Periodic abstinence (calendar, symptothermal, and post-ovulation methods), withdrawal', '(coitus interruptus), spermicides only, and lactational amenorrhoea method (LAM) are not', 'acceptable methods of contraception. Female condom and male condom should not be', 'used together.', '17. Patients committed to an institution by virtue of an order issued by either the judicial or the', 'administrative authorities will be excluded from this study.', '18.', 'Prior treatment with idelalisib.', '19.', 'Prior treatment with live vaccines within 30 days of initial administration of study drug', '(cemiplimab or IC chemo). Patients must not be treated with live vaccines during the study', 'and up to 5 half-lives following the last dose of study drug.', '20.', 'Patients with prior treatment on any clinical trial within 30 days of the initial administration', 'of study drug. Non-interventional and observational trials are acceptable.', '21. Member of the clinical site study team and/or his or her immediate family.', '6.3.', 'Premature Withdrawal from the Study', 'A patient has the right to withdraw from the study at any time, for any reason, and without', 'repercussion.', 'The investigator and/or sponsor have the right to withdraw a patient from the study if it is no longer', \"in the interest of the patient to continue in the study, or if the patient's continuation in the study\", 'places the scientific outcome of the study at risk (eg, if a patient does not or cannot follow study', 'procedures). An excessive rate of withdrawals would render the study uninterpretable; therefore,', 'unnecessary withdrawal of patients should be avoided.', 'Patients who are withdrawn prematurely from the study will be asked to complete study', 'assessments, as described in Section 7.1.4. Patients who discontinue study drug will, as feasible,', 'remain in the study, to complete the follow-up procedures (Section 7.1.4). When patients', 'Regeneron Pharmaceuticals, Inc.', 'Page 51 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'withdraw from the study (eg, to pursue treatment options not allowed in the study), they should be', 'encouraged to provide consent for os follow-up. Patients who specifically withdraw consent for', 'follow-up should notify the investigator of this decision in writing whenever possible. The', 'withdrawal of consent should be explained in detail in the medical records by the investigator, and', 'should include whether it is from further treatment only, or also from study procedures and follow-', 'up. It should also be entered in the appropriate case report form (CRF) page. If survival is being', 'assessed, use of publicly available information should only be in accordance with local law.', 'Rules for discontinuation of study treatment (permanent or temporary) are discussed in', 'Section 8.5.', '6.4.', 'Replacement of Patients', 'Patients prematurely discontinued from the study will not be replaced.', '7.', 'STUDY SCHEDULE OF EVENTS AND PROCEDURES', '7.1.', 'Schedule of Events', 'Study assessments and procedures are presented by study period and visit in Table 1 and Table 2.', 'The allowable window for all visit days and assessments is 3 business days (excluding weekends', 'and holidays), unless otherwise stated in the protocol. All other \"days\" in the protocol refer to', 'calendar days. For response assessments (CT or MRI), the window is 7 days from planned scan', 'dates (day 42 of cycles 1-4, 6, 8, 10, 12, 14, and 16).', 'Missed doses of study drug or visits will not be made up. In the case of missed doses, response', 'assessments should still follow original schedule. If a patient is unable to undergo scans within', 'the window due to logistical or medical reasons, response assessment will be obtained at the next', 'available date and before subsequent study treatment.', '7.1.1.', 'COVID-19 Adaptation', 'In light of the public health emergency related to COVID-19, the continuity of clinical study', 'conduct and oversight may require implementation of temporary or alternative mechanisms.', 'Examples of such mechanisms may include, but are not limited to, any of the following: phone', 'contact, virtual visits, telemedicine visits, online meetings, non-invasive remote monitoring', 'devices, use of local clinic or laboratory locations, and home visits by skilled staff. Additionally,', 'no waivers to deviate from protocol enrollment criteria due to COVID-19 will be granted. All', 'temporary mechanisms utilized, and deviations from planned study procedures in response to', 'COVID-19 are to be documented as being related to COVID-19 and will remain in effect only for', 'the duration of the public health emergency.', 'Regeneron Pharmaceuticals, Inc.', 'Page 52 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}